SCHEMBL20847152

SCHEMBL20847152

O=Cc1ccc2c(c1)[nH]c(=O)n2CCOC1CCCCO1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.41
P2RX3 P56373 5/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
KDM4C Q9H3R0 1/20 0.36
ALDH1A1 P00352 3/20 0.35
GAA P10253 2/20 0.35
HSD17B10 Q99714 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
KDM4E B2RXH2 2/20 0.34
GLA P06280 2/20 0.34
PTGER4 P35408 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
MAPK9 P45984 1/20 0.33
MAPT P10636 1/20 0.33
SLC22A2 O15244 1/20 0.33
NR1I2 O75469 1/20 0.33
GMNN O75496 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20847149 0.83 HPGD (0.41) HPGDP2RX3MEN1KMT2AKDM4C
SCHEMBL7058025 0.82 HPGD (0.62) HPGDMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL20847153 0.80 ALDH1A1 (0.51) HPGDMEN1KMT2AALDH1A1GAA
SCHEMBL15560499 0.77 CYP2A6 (0.41) P2RX3MEN1KMT2AKDM4CPTGER4
SCHEMBL19693362 0.77 PTGER4 (0.40) HPGDMEN1KMT2AALDH1A1GAA
SCHEMBL145355 0.75 KDM4C (0.43) P2RX3MEN1KMT2AKDM4CALDH1A1
SCHEMBL377971 0.73 KDM4C (0.43) P2RX3MEN1KMT2AKDM4CALDH1A1
SCHEMBL25598575 0.73 ALDH1A1 (0.45) HPGDMEN1KMT2AALDH1A1GAA
SCHEMBL26008011 0.73 CHRM2 (0.41) HPGDMEN1KMT2AALDH1A1GAA
SCHEMBL29519389 0.72 HPGD (0.38) HPGDMEN1KMT2AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11649251-B2 Substituted inhibitors of menin-MLL and methods of use KURA ONCOLOGY, INC. (US) 2023-05-16 US disclosed
US-11649251-B2 Substituted inhibitors of menin-MLL and methods of use KURA ONCOLOGY, INC. (US) 2023-05-16 US disclosed
US-20200216471-A1 SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE KURA ONCOLOGY, INC. 2020-07-09 US disclosed
WO-2019060365-A1 SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE KURA ONCOLOGY, INC. (US) 2019-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11649251-B2 Substituted inhibitors of menin-MLL and methods of use MLLT1, MEN1, MLLT3 HPGD 4277/4885P2RX3 4856/4885MEN1 2/4885
US-20200216471-A1 SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHODS OF USE MLLT1, MEN1, MLLT3 HPGD 4277/4885P2RX3 4856/4885MEN1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.